Journal Article
. 1998 Mar; 4(3):321-7.
doi: 10.1038/nm0398-321.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

S A Rosenberg 1 J C Yang  D J Schwartzentruber  P Hwu  F M Marincola  S L Topalian  N P Restifo  M E Dudley  S L Schwarz  P J Spiess  J R Wunderlich  M R Parkhurst  Y Kawakami  C A Seipp  J H Einhorn  D E White  
  • PMID: 9500606
  •     38 References
  •     360 citations


The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.
M Marchand, P Weynants, +7 authors, Y Humblet.
Int J Cancer, 1995 Dec 11; 63(6). PMID: 8847150
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
C M Celluzzi, J I Mayordomo, +2 authors, L D Falo.
J Exp Med, 1996 Jan 01; 183(1). PMID: 8551233    Free PMC article.
Highly Cited.
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
E Jäeger, H Bernhard, +6 authors, A Knuth.
Int J Cancer, 1996 Apr 10; 66(2). PMID: 8603805
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
J B Rao, R S Chamberlain, +5 authors, N P Restifo.
J Immunol, 1996 May 01; 156(9). PMID: 8617961    Free PMC article.
Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
X Hu, N G Chakraborty, +3 authors, B Mukherji.
Cancer Res, 1996 Jun 01; 56(11). PMID: 8653680
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.
E Jäger, M Ringhoffer, +7 authors, A Knuth.
Int J Cancer, 1996 Jul 03; 67(1). PMID: 8690525
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
M R Parkhurst, M L Salgaller, +4 authors, Y Kawakami.
J Immunol, 1996 Sep 15; 157(6). PMID: 8805655
Highly Cited.
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
M L Salgaller, F M Marincola, J N Cormier, S A Rosenberg.
Cancer Res, 1996 Oct 15; 56(20). PMID: 8840994
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.
F M Marincola, L Rivoltini, +2 authors, S A Rosenberg.
J Immunother Emphasis Tumor Immunol, 1996 Jul 01; 19(4). PMID: 8877721
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
J N Cormier, M L Salgaller, +5 authors, F M Marincola.
Cancer J Sci Am, 1997 Jan 01; 3(1). PMID: 9072306    Free PMC article.
The development of new cancer therapies based on the molecular identification of cancer regression antigens.
S A Rosenberg.
Cancer J Sci Am, 1995 Jul 01; 1(2). PMID: 9166458
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
S A Rosenberg, B S Packard, +7 authors, C A Seipp.
N Engl J Med, 1988 Dec 22; 319(25). PMID: 3264384
Highly Cited.
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.
K Deres, H Schild, +2 authors, H G Rammensee.
Nature, 1989 Nov 30; 342(6249). PMID: 2586628
Highly Cited.
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.
P Aichele, H Hengartner, R M Zinkernagel, M Schulz.
J Exp Med, 1990 May 01; 171(5). PMID: 1692084    Free PMC article.
Limiting dilution analysis of human T cells: a useful clinical tool.
C E Sharrock, E Kaminski, S Man.
Immunol Today, 1990 Aug 01; 11(8). PMID: 2206272
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
W M Kast, L Roux, +5 authors, C J Melief.
Proc Natl Acad Sci U S A, 1991 Mar 15; 88(6). PMID: 1848698    Free PMC article.
Highly Cited.
Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.
I Bourgault, A Gomez, E Gomard, J P Levy.
Clin Exp Immunol, 1991 Jun 01; 84(3). PMID: 1646086    Free PMC article.
Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.
P G Coulie, M Somville, +4 authors, T Boon.
Int J Cancer, 1992 Jan 21; 50(2). PMID: 1730522
Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct.
J J Lasarte, P Sarobe, +2 authors, F Borrás-Cuesta.
Cell Immunol, 1992 Apr 15; 141(1). PMID: 1532538
Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells.
J P Vasilakos, J G Michael.
J Immunol, 1993 Mar 15; 150(6). PMID: 8095512
Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
T Boon.
Int J Cancer, 1993 May 08; 54(2). PMID: 8486420
T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.
D Kyburz, P Aichele, +3 authors, H Pircher.
Eur J Immunol, 1993 Aug 01; 23(8). PMID: 8344359
Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
M Shirai, C D Pendleton, +3 authors, J A Berzofsky.
J Immunol, 1994 Jan 15; 152(2). PMID: 8283036
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
S A Rosenberg, J C Yang, +6 authors, D E White.
JAMA, 1994 Mar 23; 271(12). PMID: 8120958
Highly Cited.
CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma.
O Mandelboim, G Berke, +3 authors, L Eisenbach.
Nature, 1994 May 05; 369(6475). PMID: 8164742
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Y Kawakami, S Eliyahu, +5 authors, S A Rosenberg.
Proc Natl Acad Sci U S A, 1994 Apr 26; 91(9). PMID: 8170938    Free PMC article.
Highly Cited.
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
Y Kawakami, S Eliyahu, +5 authors, S A Rosenberg.
J Exp Med, 1994 Jul 01; 180(1). PMID: 7516411    Free PMC article.
Highly Cited.
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Y Kawakami, S Eliyahu, +7 authors, S A Rosenberg.
Proc Natl Acad Sci U S A, 1994 Jul 05; 91(14). PMID: 8022805    Free PMC article.
Highly Cited.
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
S A Rosenberg, J R Yannelli, +7 authors, D E White.
J Natl Cancer Inst, 1994 Aug 03; 86(15). PMID: 8028037
Highly Cited.
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
B R Minev, B J McFarland, +2 authors, N P Restifo.
Cancer Res, 1994 Aug 01; 54(15). PMID: 7518351    Free PMC article.
Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells.
W Herr, T Wölfel, +2 authors, A Knuth.
Cancer Immunol Immunother, 1994 Aug 01; 39(2). PMID: 8044834
Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients.
A Mazzocchi, F Belli, +3 authors, A Anichini.
Int J Cancer, 1994 Aug 01; 58(3). PMID: 8050813
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
L Rivoltini, Y Kawakami, +7 authors, E Appella.
J Immunol, 1995 Mar 01; 154(5). PMID: 7868898
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Y Noguchi, E C Richards, Y T Chen, L J Old.
Proc Natl Acad Sci U S A, 1995 Mar 14; 92(6). PMID: 7892250    Free PMC article.
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Y Kawakami, S Eliyahu, +7 authors, S A Rosenberg.
J Immunol, 1995 Apr 15; 154(8). PMID: 7706734
Highly Cited.
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
V Bronte, K Tsung, +4 authors, N P Restifo.
J Immunol, 1995 May 15; 154(10). PMID: 7730632    Free PMC article.
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
M L Salgaller, A Afshar, +3 authors, S A Rosenberg.
Cancer Res, 1995 Nov 01; 55(21). PMID: 7585538
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
K R Irvine, J B Rao, S A Rosenberg, N P Restifo.
J Immunol, 1996 Jan 01; 156(1). PMID: 8598468    Free PMC article.
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
W W Overwijk, A Tsung, +8 authors, N P Restifo.
J Exp Med, 1998 Jul 22; 188(2). PMID: 9670040    Free PMC article.
Highly Cited.
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
R Lupetti, P Pisarra, +7 authors, C Traversari.
J Exp Med, 1998 Sep 22; 188(6). PMID: 9743519    Free PMC article.
Sequence analysis of genes encoding rodent homologues of the human tumor-rejection antigen SART-1.
M Gotoh, S Shichijo, +6 authors, K Itoh.
Jpn J Cancer Res, 1998 Oct 10; 89(8). PMID: 9765622    Free PMC article.
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
V Bronte, M Wang, +4 authors, N P Restifo.
J Immunol, 1998 Nov 20; 161(10). PMID: 9820504    Free PMC article.
Highly Cited.
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
S A Rosenberg, Y Zhai, +9 authors, D E White.
J Natl Cancer Inst, 1998 Dec 23; 90(24). PMID: 9862627    Free PMC article.
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
D B Chappell, T Z Zaks, S A Rosenberg, N P Restifo.
Cancer Res, 1999 Jan 19; 59(1). PMID: 9892185    Free PMC article.
Developing recombinant and synthetic vaccines for the treatment of melanoma.
N P Restifo, S A Rosenberg.
Curr Opin Oncol, 1999 Jan 23; 11(1). PMID: 9914879    Free PMC article.
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.
R Pieper, R E Christian, +7 authors, S L Topalian.
J Exp Med, 1999 Mar 02; 189(5). PMID: 10049939    Free PMC article.
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
S Manici, T Sturniolo, +8 authors, M P Protti.
J Exp Med, 1999 Mar 02; 189(5). PMID: 10049951    Free PMC article.
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
K Shimizu, R C Fields, M Giedlin, J J Mulé.
Proc Natl Acad Sci U S A, 1999 Mar 03; 96(5). PMID: 10051630    Free PMC article.
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
W W Overwijk, D S Lee, +7 authors, N P Restifo.
Proc Natl Acad Sci U S A, 1999 Mar 17; 96(6). PMID: 10077623    Free PMC article.
Expression of the SART-1 antigens in uterine cancers.
H Matsumoto, S Shichijo, +3 authors, K Itoh.
Jpn J Cancer Res, 1999 Mar 19; 89(12). PMID: 10081490    Free PMC article.
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
V Bronte, D B Chappell, +4 authors, N P Restifo.
J Immunol, 1999 May 07; 162(10). PMID: 10229805    Free PMC article.
Highly Cited.
Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.
R F Wang, X Wang, S A Rosenberg.
J Exp Med, 1999 May 20; 189(10). PMID: 10330445    Free PMC article.
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
K R Irvine, M R Parkhurst, +10 authors, N P Restifo.
Cancer Res, 1999 Jun 11; 59(11). PMID: 10363968    Free PMC article.
Will modern cancer vaccines reach clinical practice?
G Masucci.
Med Oncol, 1999 Jun 26; 16(1). PMID: 10382937
Cancer therapy using a self-replicating RNA vaccine.
H Ying, T Z Zaks, +5 authors, N P Restifo.
Nat Med, 1999 Jul 08; 5(7). PMID: 10395329    Free PMC article.
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.
M V Dhodapkar, R M Steinman, +8 authors, N Bhardwaj.
J Clin Invest, 1999 Jul 20; 104(2). PMID: 10411546    Free PMC article.
Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.
H N Lode, R Xiang, +3 authors, R A Reisfeld.
Proc Natl Acad Sci U S A, 1999 Jul 21; 96(15). PMID: 10411920    Free PMC article.
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
S A Rosenberg, J C Yang, +12 authors, D E White.
J Immunol, 1999 Jul 22; 163(3). PMID: 10415076    Free PMC article.
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.
G Hartmann, G J Weiner, A M Krieg.
Proc Natl Acad Sci U S A, 1999 Aug 04; 96(16). PMID: 10430938    Free PMC article.
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.
Z Wang, F M Marincola, +2 authors, S Ferrone.
J Exp Med, 1999 Aug 04; 190(2). PMID: 10432284    Free PMC article.
Cancer gene and immunotherapy: recent developments.
P Jantscheff, R Herrmann, C Rochlitz.
Med Oncol, 1999 Aug 24; 16(2). PMID: 10456655
Interleukin-10: a cytokine used by tumors to escape immunosurveillance.
F Salazar-Onfray.
Med Oncol, 1999 Aug 24; 16(2). PMID: 10456656
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
A Anichini, A Molla, +8 authors, G Parmiani.
J Exp Med, 1999 Sep 08; 190(5). PMID: 10477550    Free PMC article.
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.
D E Speiser, M J Pittet, +7 authors, P Romero.
J Exp Med, 1999 Sep 28; 190(6). PMID: 10499916    Free PMC article.
Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
K Matsunaga, M Nakao, +5 authors, K Itoh.
Jpn J Cancer Res, 1999 Nov 07; 90(9). PMID: 10551332    Free PMC article.
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
H L Kaufman, J B Rao, +4 authors, K R Irivine.
J Immunother, 1999 Nov 26; 22(6). PMID: 10570747    Free PMC article.
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
V Bronte, E Apolloni, +5 authors, P Zanovello.
Cancer Res, 2000 Feb 10; 60(2). PMID: 10667570    Free PMC article.
The future of interleukin-2: enhancing therapeutic anticancer vaccines.
W W Overwijk, M R Theoret, N P Restifo.
Cancer J Sci Am, 2000 Feb 24; 6 Suppl 1. PMID: 10685664    Free PMC article.
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
T F Gajewski.
Clin Diagn Lab Immunol, 2000 Mar 07; 7(2). PMID: 10702484    Free PMC article.
Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
T Asai, W J Storkus, T L Whiteside.
Clin Diagn Lab Immunol, 2000 Mar 07; 7(2). PMID: 10702485    Free PMC article.
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70.
Y Moroi, M Mayhew, +5 authors, A N Houghton.
Proc Natl Acad Sci U S A, 2000 Mar 22; 97(7). PMID: 10725409    Free PMC article.
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
C E Touloukian, W W Leitner, +4 authors, N P Restifo.
J Immunol, 2000 Mar 22; 164(7). PMID: 10725708    Free PMC article.
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.
T A Colella, T N Bullock, +6 authors, V H Engelhard.
J Exp Med, 2000 Apr 05; 191(7). PMID: 10748239    Free PMC article.
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.
B Minev, J Hipp, +3 authors, M Zanetti.
Proc Natl Acad Sci U S A, 2000 Apr 12; 97(9). PMID: 10759561    Free PMC article.
Expression of SART3 tumor-rejection antigen in gastric cancers.
F Niiya, S Nishizaka, +5 authors, K Itoh.
Jpn J Cancer Res, 2000 Apr 13; 91(3). PMID: 10760694    Free PMC article.
Mouse homologue of the human SART3 gene encoding tumor-rejection antigen.
K Harada, A Yamada, +3 authors, K Itoh.
Jpn J Cancer Res, 2000 Apr 13; 91(2). PMID: 10761712    Free PMC article.
A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.
A Moreau-Aubry, S Le Guiner, +3 authors, R Breathnach.
J Exp Med, 2000 May 03; 191(9). PMID: 10790436    Free PMC article.
Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.
T L Whiteside.
Clin Diagn Lab Immunol, 2000 May 09; 7(3). PMID: 10799441    Free PMC article.
Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma.
Y Nabeta, H Sahara, +10 authors, N Sato.
Jpn J Cancer Res, 2000 Jun 30; 91(6). PMID: 10874214    Free PMC article.
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
G Zeng, C E Touloukian, +3 authors, R F Wang.
J Immunol, 2000 Jul 06; 165(2). PMID: 10878395    Free PMC article.
New methods for assessing T-cell responses.
N Bercovici, M T Duffour, +2 authors, J P Abastado.
Clin Diagn Lab Immunol, 2000 Nov 04; 7(6). PMID: 11063487    Free PMC article.
Expression of tumor-rejection antigens in gynecologic cancers.
S Tanaka, N Tsuda, +6 authors, K Itoh.
Jpn J Cancer Res, 2000 Nov 28; 91(11). PMID: 11092984    Free PMC article.
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
C Yee, J A Thompson, +7 authors, P D Greenberg.
J Exp Med, 2000 Dec 06; 192(11). PMID: 11104805    Free PMC article.
Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.
A L Zarling, S B Ficarro, +3 authors, V H Engelhard.
J Exp Med, 2000 Dec 20; 192(12). PMID: 11120772    Free PMC article.
Melanoma peptide vaccines: from preclinical background to clinical trials.
J Weber.
Curr Oncol Rep, 2000 Dec 21; 2(1). PMID: 11122823
Preventing relapse in melanoma.
J Stebbing, M Gore.
Curr Oncol Rep, 2000 Dec 21; 2(3). PMID: 11122845
Vaccination for melanoma.
L W Thompson, L Brinckerhoff, C L Slingluff.
Curr Oncol Rep, 2000 Dec 21; 2(4). PMID: 11122856
Targeting pediatric malignancies for T cell-mediated immune responses.
C L Mackall, L J Helman.
Curr Oncol Rep, 2000 Dec 21; 2(6). PMID: 11122890
Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas.
H Tanaka, T Tsunoda, +6 authors, H Tanimura.
Br J Cancer, 2001 Jan 05; 84(1). PMID: 11139320    Free PMC article.
Molecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus.
D Hudrisier, J Riond, J E Gairin.
J Virol, 2001 Feb 13; 75(5). PMID: 11160751    Free PMC article.
Immunotherapy for colorectal cancer.
K A Foon.
Curr Oncol Rep, 2001 Mar 20; 3(2). PMID: 11177743
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
K L Knutson, K Schiffman, M L Disis.
J Clin Invest, 2001 Feb 22; 107(4). PMID: 11181647    Free PMC article.
Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells.
M Takenoyama, I Yoshino, +10 authors, K Yasumoto.
Jpn J Cancer Res, 2001 Mar 27; 92(3). PMID: 11267941    Free PMC article.
Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
Y Suefuji, T Sasatomi, +5 authors, K Itoh.
Br J Cancer, 2001 Apr 05; 84(7). PMID: 11286471    Free PMC article.
Creating therapeutic cancer vaccines: notes from the battlefield.
W W Overwijk, N P Restifo.
Trends Immunol, 2001 Apr 05; 22(1). PMID: 11286676    Free PMC article.
Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Y Umano, T Tsunoda, +3 authors, H Tanimura.
Br J Cancer, 2001 Apr 20; 84(8). PMID: 11308253    Free PMC article.
Hierarchy, tolerance, and dominance in the antitumor T-cell response.
N P Restifo.
J Immunother, 2001 Jun 08; 24(3). PMID: 11394495    Free PMC article.
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
W W Overwijk, N P Restifo.
Crit Rev Immunol, 2001 Jun 09; 20(6). PMID: 11396680    Free PMC article.
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
L Fong, Y Hou, +5 authors, E G Engleman.
Proc Natl Acad Sci U S A, 2001 Jun 28; 98(15). PMID: 11427731    Free PMC article.
Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
M Tamura, S Nishizaka, +5 authors, K Itoh.
Jpn J Cancer Res, 2001 Jul 28; 92(7). PMID: 11473727    Free PMC article.
Progress in cancer vaccines by enhanced self-presentation.
S R Riddell.
Proc Natl Acad Sci U S A, 2001 Aug 02; 98(16). PMID: 11481463    Free PMC article.
Immunotherapy of melanoma.
C Smith, V Cerundolo.
Immunology, 2001 Sep 29; 104(1). PMID: 11576213    Free PMC article.
Immunization against endogenous retroviral tumor-associated antigens.
M H Kershaw, C Hsu, +8 authors, P Hwu.
Cancer Res, 2001 Nov 03; 61(21). PMID: 11691813    Free PMC article.
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
K Liu, S A Rosenberg.
J Immunol, 2001 Nov 21; 167(11). PMID: 11714800    Free PMC article.
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
C E Touloukian, W W Leitner, +2 authors, N P Restifo.
Cancer Res, 2001 Nov 24; 61(22). PMID: 11719435    Free PMC article.
Intensity of the vaccine-elicited immune response determines tumor clearance.
Ainhoa Perez-Diez, Paul J Spiess, +2 authors, Francesco M Marincola.
J Immunol, 2001 Dec 26; 168(1). PMID: 11751979    Free PMC article.
Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells.
M Schmitz, J Rohayem, +3 authors, E P Rieber.
J Clin Lab Anal, 2002 Feb 09; 16(1). PMID: 11835528    Free PMC article.
Thymic selection generates a large T cell pool recognizing a self-peptide in humans.
Alfred Zippelius, Mikaël J Pittet, +11 authors, Pedro Romero.
J Exp Med, 2002 Feb 21; 195(4). PMID: 11854361    Free PMC article.
Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis.
H Pilch, H Höhn, +6 authors, M J Maeurer.
Clin Diagn Lab Immunol, 2002 Mar 05; 9(2). PMID: 11874861    Free PMC article.
Progress in the development of immunotherapy for the treatment of patients with cancer.
S A Rosenberg.
J Intern Med, 2002 Mar 21; 250(6). PMID: 11902815    Free PMC article.
Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
Smita K Nair, Michael Morse, +4 authors, H Kim Lyerly.
Ann Surg, 2002 Mar 30; 235(4). PMID: 11923611    Free PMC article.
Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.
Stacy E Thurber, Hung T Khong, Udai S Kammula, Steven A Rosenberg.
J Immunother, 2002 Apr 02; 25(1). PMID: 11924911    Free PMC article.
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.
Lisa M Guirguis, James C Yang, +4 authors, Douglas J Schwartzentruber.
J Immunother, 2002 Apr 02; 25(1). PMID: 11924913    Free PMC article.
Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.
P Savage, P Cowburn, +5 authors, G Ogg.
Br J Cancer, 2002 Apr 16; 86(8). PMID: 11953895    Free PMC article.
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
F Stephen Hodi, Jan C Schmollinger, +8 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2002 May 02; 99(10). PMID: 11983866    Free PMC article.
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
Mark E Dudley, John R Wunderlich, +13 authors, Steven A Rosenberg.
J Immunother, 2002 May 10; 25(3). PMID: 12000866    Free PMC article.
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Simone Seiter, Vladia Monsurro, +5 authors, Francesco M Marincola.
J Immunother, 2002 May 10; 25(3). PMID: 12000867    Free PMC article.
Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.
Carlos E Marroquin, Jennifer A Westwood, +5 authors, Patrick Hwu.
J Immunother, 2002 May 10; 25(3). PMID: 12000870    Free PMC article.
Functional heterogeneity of vaccine-induced CD8(+) T cells.
Vladia Monsurrò, Dirk Nagorsen, +4 authors, Francesco M Marincola.
J Immunol, 2002 May 23; 168(11). PMID: 12023400    Free PMC article.
The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
Hung T Khong, Steven A Rosenberg.
Cancer Res, 2002 May 31; 62(11). PMID: 12036907    Free PMC article.
Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.
M Harada, K Tatsugami, M Nomoto, K Nomoto.
Clin Exp Immunol, 2002 Jun 04; 128(2). PMID: 12041507    Free PMC article.
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.
Helen Y Wang, Tihui Fu, +6 authors, Rong-Fu Wang.
J Clin Invest, 2002 Jun 05; 109(11). PMID: 12045260    Free PMC article.
Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.
David M Weinreich, Steven A Rosenberg.
J Immunother, 2002 Jun 21; 25(2). PMID: 12074048    Free PMC article.
Generation of dendritic cell-based vaccines for cancer therapy.
G Reinhard, A Märten, +3 authors, I G H Schmidt-Wolf.
Br J Cancer, 2002 Jun 27; 86(10). PMID: 12085199    Free PMC article.
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
M Lotem, T Peretz, +8 authors, E Shiloni.
Br J Cancer, 2002 Jun 27; 86(10). PMID: 12085200    Free PMC article.
Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
Gang Zeng, Yong Li, +5 authors, Paul F Robbins.
Cancer Res, 2002 Jul 05; 62(13). PMID: 12097265    Free PMC article.
Cancer vaccines: progress reveals new complexities.
Zhiya Yu, Nicholas P Restifo.
J Clin Invest, 2002 Aug 07; 110(3). PMID: 12163445    Free PMC article.
Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker.
F Salazar-Onfray, M López, +8 authors, R Kiessling.
Br J Cancer, 2002 Aug 15; 87(4). PMID: 12177778    Free PMC article.
Rational design of peptide-based tumor vaccines.
Wilson S Meng, Lisa H Butterfield.
Pharm Res, 2002 Aug 16; 19(7). PMID: 12180543
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration.
Monica C Panelli, Ena Wang, +5 authors, Francesco M Marincola.
Genome Biol, 2002 Aug 20; 3(7). PMID: 12184809    Free PMC article.
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
Sacha Gnjatic, Elke Jäger, +11 authors, Lloyd J Old.
Proc Natl Acad Sci U S A, 2002 Aug 21; 99(18). PMID: 12186971    Free PMC article.
Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients.
Y Maeda, N Hida, +8 authors, K Itoh.
Br J Cancer, 2002 Sep 17; 87(7). PMID: 12232766    Free PMC article.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Mark E Dudley, John R Wunderlich, +16 authors, Steven A Rosenberg.
Science, 2002 Sep 21; 298(5594). PMID: 12242449    Free PMC article.
Highly Cited.
MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells.
J Mark Sloan, Michael H Kershaw, +4 authors, Patrick Hwu.
Cancer Gene Ther, 2002 Oct 19; 9(11). PMID: 12386833    Free PMC article.
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
C Yee, J A Thompson, +4 authors, P D Greenberg.
Proc Natl Acad Sci U S A, 2002 Nov 13; 99(25). PMID: 12427970    Free PMC article.
Highly Cited.
CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
Luv Ram Javia, Steven A Rosenberg.
J Immunother, 2003 Jan 07; 26(1). PMID: 12514432    Free PMC article.
Prospects for immunotherapy of malignant disease.
E C Morris, G M Bendle, H J Stauss.
Clin Exp Immunol, 2003 Jan 10; 131(1). PMID: 12519379    Free PMC article.
Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers.
Y Shono, H Tanimura, +5 authors, H Yamaue.
Br J Cancer, 2003 Feb 20; 88(4). PMID: 12592366    Free PMC article.
Therapeutic vaccination with tumor cells that engage CD137.
Karl Erik Hellstrom, Ingegerd Hellstrom.
J Mol Med (Berl), 2003 Feb 26; 81(2). PMID: 12601523
Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.
Salem Chouaib.
J Clin Invest, 2003 Mar 06; 111(5). PMID: 12618511    Free PMC article.
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Jeffrey J Molldrem, Peter P Lee, +5 authors, Mark M Davis.
J Clin Invest, 2003 Mar 06; 111(5). PMID: 12618518    Free PMC article.
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.
Douglas G McNeel, Keith L Knutson, +3 authors, Mary L Disis.
J Clin Immunol, 2003 Mar 21; 23(1). PMID: 12645861
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.
József Tímár, Andrea Ladányi, +2 authors, László Kopper.
Pathol Oncol Res, 2003 Apr 22; 9(1). PMID: 12704448
Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.
Jennifer Carlring, Munitta Shaif-Muthana, +2 authors, Anna K Murray.
Immunology, 2003 Apr 24; 109(1). PMID: 12709016    Free PMC article.
Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes.
Marie Louise Andersen, Morten Ruhwald, +4 authors, Mogens H Claesson.
J Immune Based Ther Vaccines, 2003 Apr 24; 1(1). PMID: 12709261    Free PMC article.
Melanoma: adjuvant therapy and other treatment options.
Alicia Terando, Michael S Sabel, Vernon K Sondak.
Curr Treat Options Oncol, 2003 Apr 30; 4(3). PMID: 12718796
Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
Maria R Parkhurst, Cormac DePan, +2 authors, Suyu Shu.
J Immunol, 2003 May 08; 170(10). PMID: 12734382    Free PMC article.
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.
Christoph Esslinger, Laurence Chapatte, +4 authors, H Robson MacDonald.
J Clin Invest, 2003 Jun 05; 111(11). PMID: 12782670    Free PMC article.
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Steven A Rosenberg, James C Yang, +10 authors, Donald E White.
Hum Gene Ther, 2003 Jun 14; 14(8). PMID: 12804135    Free PMC article.
Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.
Ke Liu, Steven A Rosenberg.
J Immunother, 2003 Jun 14; 26(3). PMID: 12806273    Free PMC article.
MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
P Mukherjee, A R Ginardi, +6 authors, S J Gendler.
Glycoconj J, 2003 Jun 25; 18(11-12). PMID: 12820727
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
Identification of human tumor antigens recognized by T-cells and their use for immunotherapy.
Yutaka Kawakami.
Int J Hematol, 2003 Jul 05; 77(5). PMID: 12841379
Importance of CD4+ helper T-cells in antitumor immunity.
Hiroshi Shiku.
Int J Hematol, 2003 Jul 05; 77(5). PMID: 12841380
Immunotherapy for lymphomas.
John M Timmerman.
Int J Hematol, 2003 Jul 05; 77(5). PMID: 12841382
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
Giao Q Phan, Christopher E Touloukian, +11 authors, Steven A Rosenberg.
J Immunother, 2003 Jul 05; 26(4). PMID: 12843797    Free PMC article.
A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.
Robert H Vonderheide, Carl H June.
Immunol Res, 2003 Jul 15; 27(2-3). PMID: 12857980
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Steven A Rosenberg, James C Yang, +12 authors, Donald E White.
Clin Cancer Res, 2003 Aug 13; 9(8). PMID: 12912944    Free PMC article.
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
Willem W Overwijk, Marc R Theoret, +15 authors, Nicholas P Restifo.
J Exp Med, 2003 Aug 20; 198(4). PMID: 12925674    Free PMC article.
Highly Cited.
Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Dajing Xia, Shu Zheng, +6 authors, Xuetao Cao.
J Mol Med (Berl), 2003 Aug 26; 81(9). PMID: 12937899
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
D Nagorsen, M Panelli, +3 authors, F M Marincola.
Gene Ther, 2003 Aug 27; 10(20). PMID: 12939642    Free PMC article.
Adoptive-cell-transfer therapy for the treatment of patients with cancer.
Mark E Dudley, Steven A Rosenberg.
Nat Rev Cancer, 2003 Sep 03; 3(9). PMID: 12951585    Free PMC article.
Highly Cited. Review.
The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer.
Michael Girardi, Earl Glusac, +5 authors, Adrian C Hayday.
J Exp Med, 2003 Sep 04; 198(5). PMID: 12953094    Free PMC article.
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Richard A Morgan, Mark E Dudley, +7 authors, Steven A Rosenberg.
J Immunol, 2003 Sep 10; 171(6). PMID: 12960359    Free PMC article.
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Steven A Rosenberg, James C Yang, +9 authors, Mark E Dudley.
J Immunother, 2003 Sep 16; 26(5). PMID: 12973027    Free PMC article.
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
Daniel J Powell, Steven A Rosenberg.
J Immunother, 2003 Dec 17; 27(1). PMID: 14676632    Free PMC article.
Costimulation-based immunotherapy for head and neck cancer.
Scott E Strome, Lieping Chen.
Curr Treat Options Oncol, 2003 Dec 31; 5(1). PMID: 14697154
Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.
M Adamina, M Bolli, +10 authors, G C Spagnoli.
Br J Cancer, 2004 Jan 08; 90(1). PMID: 14710238    Free PMC article.
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
David-Alexandre Gross, Stéphanie Graff-Dubois, +12 authors, Kostas Kosmatopoulos.
J Clin Invest, 2004 Feb 03; 113(3). PMID: 14755339    Free PMC article.
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.
M Lotem, E Shiloni, +8 authors, T Peretz.
Br J Cancer, 2004 Feb 19; 90(4). PMID: 14970852    Free PMC article.
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.
Y Sato, Y Maeda, +14 authors, S Todo.
Br J Cancer, 2004 Apr 01; 90(7). PMID: 15054451    Free PMC article.
Shedding light on immunotherapy for cancer.
Steven A Rosenberg.
N Engl J Med, 2004 Apr 09; 350(14). PMID: 15070799    Free PMC article.
T-cell clonotypes in cancer.
Per Thor Straten, David Schrama, Mads Hald Andersen, Jürgen C Becker.
J Transl Med, 2004 Apr 10; 2(1). PMID: 15072580    Free PMC article.
Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
Hung T Khong, Qiong J Wang, Steven A Rosenberg.
J Immunother, 2004 Apr 13; 27(3). PMID: 15076135    Free PMC article.
Development of effective immunotherapy for the treatment of patients with cancer.
Steven A Rosenberg.
J Am Coll Surg, 2004 Apr 28; 198(5). PMID: 15110801    Free PMC article.
Immunotherapy in non-renal carcinomas.
U Keilholz.
Urologe A, 2004 May 19; 43 Suppl 3. PMID: 15148577
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.
Sophie Paczesny, Jacques Banchereau, +3 authors, A Karolina Palucka.
J Exp Med, 2004 Jun 03; 199(11). PMID: 15173207    Free PMC article.
Progress on new vaccine strategies for the immunotherapy and prevention of cancer.
Jay A Berzofsky, Masaki Terabe, +4 authors, John C Morris.
J Clin Invest, 2004 Jun 03; 113(11). PMID: 15173875    Free PMC article.
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration.
Monica C Panelli, Richard White, +4 authors, Francesco M Marincola.
J Transl Med, 2004 Jun 04; 2(1). PMID: 15175100    Free PMC article.
Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
Avital Lev, Roy Noy, +5 authors, Yoram Reiter.
Proc Natl Acad Sci U S A, 2004 Jun 09; 101(24). PMID: 15184663    Free PMC article.
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
Tetsuhiro Tsuruma, Fumitake Hata, +20 authors, Koichi Hirata.
J Transl Med, 2004 Jun 15; 2(1). PMID: 15193151    Free PMC article.
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
James T Snyder, Igor M Belyakov, +2 authors, Jay A Berzofsky.
J Virol, 2004 Jun 15; 78(13). PMID: 15194781    Free PMC article.
Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.
A Yao, M Harada, +7 authors, K Itoh.
Br J Cancer, 2004 Jun 17; 91(2). PMID: 15199397    Free PMC article.
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Maria R Parkhurst, John P Riley, +3 authors, Steven A Rosenberg.
Clin Cancer Res, 2004 Jul 23; 10(14). PMID: 15269141    Free PMC article.
Overview of melanoma vaccines and promising approaches.
Monica C Panelli, Ena Wang, +5 authors, Francesco M Marincola.
Curr Oncol Rep, 2004 Aug 05; 6(5). PMID: 15291987
Therapeutic cancer vaccines: using unique antigens.
Jonathan J Lewis.
Proc Natl Acad Sci U S A, 2004 Aug 07; 101 Suppl 2. PMID: 15297620    Free PMC article.
Identification of HLA-Cw6.02 and HLA-Cw7.01 allele-specific binding motifs by screening synthetic peptide libraries.
Sara O Dionne, Douglas F Lake, William J Grimes, Margaret H Smith.
Immunogenetics, 2004 Aug 17; 56(6). PMID: 15309347
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
Zhiya Yu, Marc R Theoret, +6 authors, Nicholas P Restifo.
J Clin Invest, 2004 Aug 18; 114(4). PMID: 15314692    Free PMC article.
Cancer immunotherapy: moving beyond current vaccines.
Steven A Rosenberg, James C Yang, Nicholas P Restifo.
Nat Med, 2004 Sep 02; 10(9). PMID: 15340416    Free PMC article.
Highly Cited.
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Steven A Rosenberg, Mark E Dudley.
Proc Natl Acad Sci U S A, 2004 Sep 24; 101 Suppl 2. PMID: 15381769    Free PMC article.
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Hung T Khong, James C Yang, +4 authors, Steven A Rosenberg.
J Immunother, 2004 Nov 10; 27(6). PMID: 15534491    Free PMC article.
Diversity and recognition efficiency of T cell responses to cancer.
Tor B Stuge, Susan P Holmes, +4 authors, Peter P Lee.
PLoS Med, 2004 Dec 04; 1(2). PMID: 15578105    Free PMC article.
Understanding the response to immunotherapy in humans.
Ena Wang, Monica C Panelli, Francesco M Marincola.
Springer Semin Immunopathol, 2005 Jan 25; 27(1). PMID: 15666150
Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives.
Roberto Baccala, Rosana Gonzalez-Quintial, Wolfgang Dummer, Argyrios N Theofilopoulos.
Springer Semin Immunopathol, 2005 Jan 25; 27(1). PMID: 15666151
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Daniel E Speiser, Danielle Liénard, +6 authors, Pedro Romero.
J Clin Invest, 2005 Feb 08; 115(3). PMID: 15696196    Free PMC article.
Highly Cited.
Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.
Ken-ichi Hanada, James C Yang.
J Mol Med (Berl), 2005 Mar 11; 83(6). PMID: 15759099
Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
B Li, Y Wang, +2 authors, W Chen.
Clin Exp Immunol, 2005 Apr 06; 140(2). PMID: 15807856    Free PMC article.
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
Oleg Y Borbulevych, Tiffany K Baxter, +2 authors, Brian M Baker.
J Immunol, 2005 Apr 09; 174(8). PMID: 15814707    Free PMC article.
Improving outcomes in advanced malignant melanoma: update on systemic therapy.
Sarah Danson, Paul Lorigan.
Drugs, 2005 Apr 12; 65(6). PMID: 15819587
A balanced review of the status T cell-based therapy against cancer.
Francesco M Marincola.
J Transl Med, 2005 Apr 16; 3(1). PMID: 15831096    Free PMC article.
Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
Ji-Li Chen, Guillaume Stewart-Jones, +16 authors, Vincenzo Cerundolo.
J Exp Med, 2005 Apr 20; 201(8). PMID: 15837811    Free PMC article.
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
Mojgan Ahmadzadeh, Steven A Rosenberg.
J Immunol, 2005 Apr 22; 174(9). PMID: 15843517    Free PMC article.
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Marybeth S Hughes, Yik Y L Yu, +8 authors, Richard A Morgan.
Hum Gene Ther, 2005 May 06; 16(4). PMID: 15871677    Free PMC article.
Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation.
Giulio C Spagnoli, Michel Adamina, +6 authors, Felix Harder.
World J Surg, 2005 May 11; 29(6). PMID: 15883665
In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins.
Hiroshi Fujiwara, J Joseph Melenhorst, +8 authors, A John Barrett.
Clin Cancer Res, 2005 Jun 17; 11(12). PMID: 15958635    Free PMC article.
Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules.
Sergio Madurga, Ignasi Belda, Xavier Llorà, Ernest Giralt.
Protein Sci, 2005 Jul 28; 14(8). PMID: 16046628    Free PMC article.
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Sixun Yang, Kwong-Yok Tsang, Jeffrey Schlom.
Clin Cancer Res, 2005 Aug 03; 11(15). PMID: 16061879    Free PMC article.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Peter Attia, Giao Q Phan, +14 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087944    Free PMC article.
Highly Cited.
Fugetaxis: active movement of leukocytes away from a chemokinetic agent.
Fabrizio Vianello, Ivona T Olszak, Mark C Poznansky.
J Mol Med (Berl), 2005 Sep 06; 83(10). PMID: 16142473
T cell avidity and tumor recognition: implications and therapeutic strategies.
Mark D McKee, Jeffrey J Roszkowski, Michael I Nishimura.
J Transl Med, 2005 Sep 22; 3. PMID: 16174302    Free PMC article.
Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.
M Montes, N Rufer, +7 authors, S Leyvraz.
Clin Exp Immunol, 2005 Oct 20; 142(2). PMID: 16232216    Free PMC article.
Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas.
G N Berta, B Mognetti, +5 authors, F Cavallo.
Br J Cancer, 2005 Nov 03; 93(11). PMID: 16265350    Free PMC article.
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
A Escobar, M López, +9 authors, F Salazar-Onfray.
Clin Exp Immunol, 2005 Nov 22; 142(3). PMID: 16297169    Free PMC article.
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
Cary Hsu, Marybeth S Hughes, +3 authors, Richard A Morgan.
J Immunol, 2005 Nov 23; 175(11). PMID: 16301627    Free PMC article.
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.
K Hiraoka, M Miyamoto, +7 authors, H Katoh.
Br J Cancer, 2006 Jan 20; 94(2). PMID: 16421594    Free PMC article.
Highly Cited.
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.
Hong Shen, Anne L Ackerman, +6 authors, Douglas J Hanlon.
Immunology, 2006 Jan 21; 117(1). PMID: 16423043    Free PMC article.
Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.
Anthony Simmons, Robert P Whitehead, Andrey A Kolokoltsov, Robert A Davey.
Virol J, 2006 Mar 02; 3. PMID: 16507098    Free PMC article.
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
Steven A Rosenberg, Richard M Sherry, +10 authors, Donald E White.
J Immunother, 2006 Mar 15; 29(2). PMID: 16531823    Free PMC article.
Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu.
Matthew A Joseph, Megan L Mitchell, +4 authors, Wilson S Meng.
Mol Immunol, 2006 Apr 07; 44(4). PMID: 16597462    Free PMC article.
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
Willem W Overwijk, Karin E de Visser, +12 authors, John B A G Haanen.
J Immunol, 2006 Apr 20; 176(9). PMID: 16621986    Free PMC article.
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.
Jack C F Liao, Polly Gregor, +5 authors, Philip J Bergman.
Cancer Immun, 2006 Apr 22; 6. PMID: 16626110    Free PMC article.
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
Steven A Rosenberg, Claude Sportès, +10 authors, Ronald E Gress.
J Immunother, 2006 May 16; 29(3). PMID: 16699374    Free PMC article.
Highly Cited.
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
Hidetoshi Sumimoto, Fumie Imabayashi, Tomoko Iwata, Yutaka Kawakami.
J Exp Med, 2006 Jun 28; 203(7). PMID: 16801397    Free PMC article.
Highly Cited.
CD8+ T-cell memory in tumor immunology and immunotherapy.
Christopher A Klebanoff, Luca Gattinoni, Nicholas P Restifo.
Immunol Rev, 2006 Jul 11; 211. PMID: 16824130    Free PMC article.
Highly Cited. Review.
Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.
Katja Mauerer Zirlik, David Zahrieh, Donna Neuberg, John G Gribben.
Blood, 2006 Aug 12; 108(12). PMID: 16902144    Free PMC article.
[Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies].
K Rass, D Tadler, W Tilgen.
Hautarzt, 2006 Aug 23; 57(9). PMID: 16924435
Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells.
Shengming Dai, Xiangyang Zhou, +6 authors, Xuetao Cao.
J Mol Med (Berl), 2006 Oct 04; 84(12). PMID: 17016692    Free PMC article.
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Daniel J Powell, Mark E Dudley, +2 authors, Steven A Rosenberg.
J Immunol, 2006 Oct 24; 177(9). PMID: 17056585    Free PMC article.
Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes.
C Feder-Mengus, S Ghosh, +8 authors, A Reschner.
Br J Cancer, 2007 Mar 08; 96(7). PMID: 17342088    Free PMC article.
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.
James N Kochenderfer, Jessica L Simpson, Christopher D Chien, Ronald E Gress.
Blood, 2007 Mar 21; 110(1). PMID: 17371943    Free PMC article.
IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
Mojgan Ahmadzadeh, Paul A Antony, Steven A Rosenberg.
J Immunother, 2007 Apr 07; 30(3). PMID: 17414320    Free PMC article.
Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.
Marc Mansour, Bill Pohajdak, +5 authors, Pirouz Daftarian.
J Transl Med, 2007 Apr 25; 5. PMID: 17451606    Free PMC article.
In support of descriptive studies; relevance to translational research.
Francesco M Marincola.
J Transl Med, 2007 May 04; 5. PMID: 17474987    Free PMC article.
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
Rebecca J Critchley-Thorne, Ning Yan, +3 authors, Peter P Lee.
PLoS Med, 2007 May 10; 4(5). PMID: 17488182    Free PMC article.
Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells.
Joel Baumgartner, Cara Wilson, +3 authors, Martin McCarter.
J Surg Res, 2007 Jun 19; 141(1). PMID: 17574040    Free PMC article.
Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways.
Karen Dybkaer, Javeed Iqbal, +5 authors, Wing C Chan.
BMC Genomics, 2007 Jul 12; 8. PMID: 17623099    Free PMC article.
Mobilizing the low-avidity T cell repertoire to kill tumors.
Rachel H McMahan, Jill E Slansky.
Semin Cancer Biol, 2007 Jul 27; 17(4). PMID: 17651986    Free PMC article.
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Oleg Y Borbulevych, Francis K Insaidoo, +4 authors, Brian M Baker.
J Mol Biol, 2007 Aug 28; 372(5). PMID: 17719062    Free PMC article.
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Daniel J Powell, Aloisio Felipe-Silva, +8 authors, Ira Pastan.
J Immunol, 2007 Sep 20; 179(7). PMID: 17878392    Free PMC article.
Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.
David W O'Neill, Nina Bhardwaj.
Mol Biotechnol, 2007 Oct 05; 36(2). PMID: 17914192
Adoptive cell transfer therapy.
Mark E Dudley, Steven A Rosenberg.
Semin Oncol, 2007 Dec 18; 34(6). PMID: 18083376    Free PMC article.
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.
Daniel E Speiser, Petra Baumgaertner, +4 authors, Pedro Romero.
Proc Natl Acad Sci U S A, 2008 Mar 06; 105(10). PMID: 18319339    Free PMC article.
Cancer-testis (CT) antigen expression in medulloblastoma.
Sueli M Oba-Shinjo, Otavia L Caballero, +4 authors, Suely K N Marie.
Cancer Immun, 2008 Apr 23; 8. PMID: 18426187    Free PMC article.
Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Malka Epel, Irit Carmi, +5 authors, Yoram Reiter.
Eur J Immunol, 2008 May 01; 38(6). PMID: 18446790    Free PMC article.
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Jeffrey A Sosman, Carole Carrillo, +13 authors, Marc S Ernstoff.
J Clin Oncol, 2008 May 10; 26(14). PMID: 18467720    Free PMC article.
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
Tetsuhiro Tsuruma, Yuji Iwayama, +16 authors, Koichi Hirata.
J Transl Med, 2008 May 13; 6. PMID: 18471305    Free PMC article.
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Douglas C Palmer, Chi-Chao Chan, +11 authors, Nicholas P Restifo.
Proc Natl Acad Sci U S A, 2008 Jun 05; 105(23). PMID: 18523011    Free PMC article.
Environmental risk factors for relapse of melanoma.
Samantha Beswick, Paul Affleck, +9 authors, Julia A Newton-Bishop.
Eur J Cancer, 2008 Jul 08; 44(12). PMID: 18602256    Free PMC article.
Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization.
Edwin B Walker, Daniel Haley, +6 authors, Walter J Urba.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698047    Free PMC article.
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Franz O Smith, Stephanie G Downey, +10 authors, Steven A Rosenberg.
Clin Cancer Res, 2008 Sep 04; 14(17). PMID: 18765555    Free PMC article.
Toward development and production of human T cells in swine for potential use in adoptive T cell immunotherapy.
Brenda M Ogle, Bruce E Knudsen, +2 authors, Jeffrey L Platt.
Tissue Eng Part A, 2008 Oct 02; 15(5). PMID: 18826341    Free PMC article.
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.
Craig L Slingluff, Galina V Yamshchikov, +10 authors, Jayashree Parekh.
Ann Surg Oncol, 2008 Oct 17; 15(12). PMID: 18923873    Free PMC article.
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
Akiva Mintz, Denise M Gibo, +3 authors, Waldemar Debinski.
Cancer Biother Radiopharm, 2008 Nov 04; 23(5). PMID: 18976118    Free PMC article.
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Howard L Kaufman, Bret Taback, +9 authors, Seunghee Kim-Schulze.
J Transl Med, 2009 Jan 09; 7. PMID: 19128501    Free PMC article.
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.
Kimberly A Chianese-Bullock, Sarah T Lewis, +2 authors, Craig L Slingluff.
Vaccine, 2009 Feb 03; 27(11). PMID: 19185050    Free PMC article.
Dendritic-cell- and peptide-based vaccination strategies for glioma.
Ryuya Yamanaka.
Neurosurg Rev, 2009 Feb 14; 32(3). PMID: 19214609
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
John M Kirkwood, Sandra Lee, +6 authors, Louis Weiner.
Clin Cancer Res, 2009 Feb 21; 15(4). PMID: 19228745    Free PMC article.
Promising novel immunotherapies and combinations for prostate cancer.
Philip M Arlen, Mahsa Mohebtash, Ravi A Madan, James L Gulley.
Future Oncol, 2009 Mar 17; 5(2). PMID: 19284377    Free PMC article.
Functions of γC cytokines in immune homeostasis: current and potential clinical applications.
Willem W Overwijk, Kimberly S Schluns.
Clin Immunol, 2009 May 12; 132(2). PMID: 19428306    Free PMC article.
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Diana V Kouiavskaia, Carla A Berard, +4 authors, Richard B Alexander.
J Immunother, 2009 Jun 02; 32(6). PMID: 19483644    Free PMC article.
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
William R Burns, Zhili Zheng, Steven A Rosenberg, Richard A Morgan.
Blood, 2009 Jul 11; 114(14). PMID: 19589923    Free PMC article.
Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
Kimberly A Shafer-Weaver, Stephanie K Watkins, +5 authors, Arthur A Hurwitz.
Cancer Res, 2009 Jul 23; 69(15). PMID: 19622771    Free PMC article.
Current perspectives in prostate cancer vaccines.
Philip M Arlen, James L Gulley.
Anticancer Agents Med Chem, 2009 Sep 02; 9(10). PMID: 19719454    Free PMC article.
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Antoni Ribas, Begoña Comin-Anduix, +15 authors, Jesus Gomez-Navarro.
Clin Cancer Res, 2009 Oct 01; 15(19). PMID: 19789309    Free PMC article.
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.
Stefano Ugel, Alessia Zoso, +8 authors, Vincenzo Bronte.
Cancer Res, 2009 Nov 26; 69(24). PMID: 19934317    Free PMC article.
Clinical applications of a peptide-based vaccine for glioblastoma.
Charles W Kanaly, Dale Ding, Amy B Heimberger, John H Sampson.
Neurosurg Clin N Am, 2009 Dec 01; 21(1). PMID: 19944970    Free PMC article.
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Ichiya Honma, Toshihiko Torigoe, +6 authors, Noriyuki Sato.
J Transl Med, 2009 Dec 17; 7. PMID: 20003233    Free PMC article.
Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.
Ji-Li Chen, Anthony J Morgan, +10 authors, Vincenzo Cerundolo.
J Immunol, 2010 Jan 08; 184(4). PMID: 20053942    Free PMC article.
Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.
Kimberly R Jordan, Rachel H McMahan, +2 authors, Jill E Slansky.
Proc Natl Acad Sci U S A, 2010 Feb 06; 107(10). PMID: 20133772    Free PMC article.
Ovarian cancer immunotherapy: opportunities, progresses and challenges.
Bei Liu, John Nash, +3 authors, Zihai Li.
J Hematol Oncol, 2010 Feb 12; 3. PMID: 20146807    Free PMC article.
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.
Christian M Capitini, Terry J Fry, Crystal L Mackall.
Am J Immunol, 2010 Feb 26; 5(3). PMID: 20182648    Free PMC article.
Gene-expression profiling in vaccine therapy and immunotherapy for cancer.
Davide Bedognetti, Ena Wang, Mario Roberto Sertoli, Francesco M Marincola.
Expert Rev Vaccines, 2010 Jun 04; 9(6). PMID: 20518712    Free PMC article.
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
Steven A Rosenberg, James C Yang, +6 authors, Richard M Sherry.
J Immunother, 2010 Jun 17; 33(6). PMID: 20551834    Free PMC article.
Immunotherapy for melanoma: current status and perspectives.
Doru T Alexandrescu, Thomas E Ichim, +4 authors, Constantin A Dasanu.
J Immunother, 2010 Jun 17; 33(6). PMID: 20551839    Free PMC article.
Therapeutic cancer vaccines in combination with conventional therapy.
Mads Hald Andersen, Niels Junker, +2 authors, Per Thor Straten.
J Biomed Biotechnol, 2010 Jul 10; 2010. PMID: 20617155    Free PMC article.
TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.
Roberto Bei, Antonio Scardino.
J Biomed Biotechnol, 2010 Jul 10; 2010. PMID: 20617190    Free PMC article.
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition.
David K Cole, Emily S J Edwards, +11 authors, Andrew K Sewell.
J Immunol, 2010 Jul 20; 185(4). PMID: 20639478    Free PMC article.
Cancer immunotherapy and nanomedicine.
Wei-Yun Sheng, Leaf Huang.
Pharm Res, 2010 Sep 08; 28(2). PMID: 20821040
Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
Toshiyuki Baba, Marimo Sato-Matsushita, +5 authors, Hideaki Tahara.
J Transl Med, 2010 Sep 17; 8. PMID: 20843377    Free PMC article.
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.
Rinke Bos, Linda A Sherman.
Cancer Res, 2010 Oct 14; 70(21). PMID: 20940398    Free PMC article.
Highly Cited.
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
Jürgen Kuball, Karin de Boer, +11 authors, Matthias Theobald.
Cancer Immunol Immunother, 2010 Oct 22; 60(2). PMID: 20963411    Free PMC article.
Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.
Rikke Sick Andersen, Rikke Bæk Sørensen, +4 authors, Mads Hald Andersen.
Cancer Immunol Immunother, 2010 Oct 29; 60(2). PMID: 20981424    Free PMC article.
Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability.
Kim M Miles, John J Miles, +2 authors, David K Cole.
Mol Immunol, 2010 Dec 07; 48(4). PMID: 21130497    Free PMC article.
Therapeutic cancer vaccines: are we there yet?
Christopher A Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P Restifo.
Immunol Rev, 2011 Jan 05; 239(1). PMID: 21198663    Free PMC article.
Highly Cited. Review.
Continuous stress disrupts immunostimulatory effects of IL-12.
Ben Levi, Marganit Benish, +4 authors, Shamgar Ben-Eliyahu.
Brain Behav Immun, 2011 Feb 01; 25(4). PMID: 21277367    Free PMC article.
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Larry D Anderson, Danielle R Cook, +3 authors, Stanley R Riddell.
Cancer Immunol Immunother, 2011 Apr 05; 60(7). PMID: 21461886    Free PMC article.
Surgical management of melanoma brain metastases in patients treated with immunotherapy.
Russell R Lonser, Debbie K Song, +7 authors, Steven A Rosenberg.
J Neurosurg, 2011 Apr 12; 115(1). PMID: 21476810    Free PMC article.
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J Schwartzentruber, David H Lawson, +23 authors, Patrick Hwu.
N Engl J Med, 2011 Jun 03; 364(22). PMID: 21631324    Free PMC article.
Highly Cited.
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Osama E Rahma, Ed Ashtar, +15 authors, Samir N Khleif.
Cancer Immunol Immunother, 2011 Sep 20; 61(3). PMID: 21927947    Free PMC article.
Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.
Michael Postow, Margaret K Callahan, Jedd D Wolchok.
Cancer J, 2011 Sep 29; 17(5). PMID: 21952288    Free PMC article.
Multiple vaccinations: friend or foe.
Sarah E Church, Shawn M Jensen, +4 authors, Bernard A Fox.
Cancer J, 2011 Sep 29; 17(5). PMID: 21952289    Free PMC article.
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).
Carsten Schaefer, Lisa H Butterfield, +5 authors, Theresa L Whiteside.
Int J Cancer, 2011 Oct 25; 131(4). PMID: 22021080    Free PMC article.
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.
Charlotte Lemech, Hendrik-Tobias Arkenau.
Clin Med Insights Oncol, 2012 Jan 19; 6. PMID: 22253555    Free PMC article.
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Helen Y Wang, Rong-Fu Wang.
Adv Immunol, 2012 Mar 28; 114. PMID: 22449781    Free PMC article.
From genes to drugs: targeted strategies for melanoma.
Keith T Flaherty, F Stephen Hodi, David E Fisher.
Nat Rev Cancer, 2012 Apr 06; 12(5). PMID: 22475929
Highly Cited. Review.
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Jürgen C Becker, Mads H Andersen, +12 authors, Selma Ugurel.
Cancer Immunol Immunother, 2012 May 09; 61(11). PMID: 22565484    Free PMC article.
Hypoxia promotes tumor growth in linking angiogenesis to immune escape.
Salem Chouaib, Yosra Messai, +3 authors, Muhammad Zaeem Noman.
Front Immunol, 2012 May 09; 3. PMID: 22566905    Free PMC article.
Immunotherapy of cancer in 2012.
John M Kirkwood, Lisa H Butterfield, +3 authors, Soldano Ferrone.
CA Cancer J Clin, 2012 May 12; 62(5). PMID: 22576456    Free PMC article.
Highly Cited. Review.
Antioxidant and immunity activities of Fufang Kushen Injection Liquid.
Shen-Kang Zhou, Rui-Li Zhang, Yun-Feng Xu, Tie-Nan Bi.
Molecules, 2012 Jun 26; 17(6). PMID: 22728348    Free PMC article.
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.
Leeann T Blalock, Jennifer Landsberg, +6 authors, Lisa H Butterfield.
Oncoimmunology, 2012 Jun 28; 1(3). PMID: 22737604    Free PMC article.
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.
Julia Ekeruche-Makinde, Mathew Clement, +17 authors, Andrew K Sewell.
J Biol Chem, 2012 Sep 07; 287(44). PMID: 22952231    Free PMC article.
Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice.
Sujin Lee, Kate L Stokes, +4 authors, Martin L Moore.
J Virol, 2012 Sep 28; 86(23). PMID: 23015695    Free PMC article.
Cancer vaccines and T cell therapy.
Katayoun Rezvani, Joshua D Brody, +9 authors, John Barrett.
Biol Blood Marrow Transplant, 2012 Oct 09; 19(1 Suppl). PMID: 23041602    Free PMC article.
Dendritic cell-based vaccines: barriers and opportunities.
Jessica A Cintolo, Jashodeep Datta, Sarah J Mathew, Brian J Czerniecki.
Future Oncol, 2012 Nov 08; 8(10). PMID: 23130928    Free PMC article.
An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform.
Arthur Fridman, Adam C Finnefrock, +6 authors, Luigi Aurisicchio.
Oncoimmunology, 2012 Dec 18; 1(8). PMID: 23243589    Free PMC article.
Prediction of peptides binding to MHC class I and II alleles by temporal motif mining.
Cem Meydan, Hasan H Otu, Osman Uğur Sezerman.
BMC Bioinformatics, 2013 Feb 13; 14 Suppl 2. PMID: 23368521    Free PMC article.
Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination.
Yu-Zhe Chen, Gui-Xin Ruan, +4 authors, Jian-Qing Gao.
Pharm Res, 2013 Feb 02; 30(6). PMID: 23371516
Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer.
Laura M Rogers, Alicia K Olivier, David K Meyerholz, Adam J Dupuy.
J Immunol, 2013 Mar 12; 190(8). PMID: 23475219    Free PMC article.
Proteasomal cleavage site prediction of protein antigen using BP neural network based on a new set of amino acid descriptor.
Yuanqiang Wang, Yong Lin, +3 authors, Zhihua Lin.
J Mol Model, 2013 Apr 16; 19(8). PMID: 23584554
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
Luis M Vence, Chiyu Wang, +18 authors, Patrick Hwu.
J Immunother, 2013 Apr 23; 36(4). PMID: 23603862    Free PMC article.
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
Guru Sonpavde, Mingjun Wang, +9 authors, Teresa G Hayes.
Invest New Drugs, 2013 Apr 24; 32(2). PMID: 23609828    Free PMC article.
Optimal management of metastatic melanoma: current strategies and future directions.
Marta Batus, Salman Waheed, +3 authors, Howard L Kaufman.
Am J Clin Dermatol, 2013 May 17; 14(3). PMID: 23677693    Free PMC article.
Improvement of cancer immunotherapy by combining molecular targeted therapy.
Yutaka Kawakami, Tomonori Yaguchi, +8 authors, Naoshi Kawamura.
Front Oncol, 2013 Jun 12; 3. PMID: 23755373    Free PMC article.
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.
Beatriz M Carreno, Michelle Becker-Hapak, +7 authors, Gerald P Linette.
J Clin Invest, 2013 Jul 23; 123(8). PMID: 23867552    Free PMC article.
Therapeutic cancer vaccines: past, present, and future.
Chunqing Guo, Masoud H Manjili, +3 authors, Xiang-Yang Wang.
Adv Cancer Res, 2013 Jul 23; 119. PMID: 23870514    Free PMC article.
Highly Cited. Review.
Dendritic-cell-based therapeutic cancer vaccines.
Karolina Palucka, Jacques Banchereau.
Immunity, 2013 Jul 31; 39(1). PMID: 23890062    Free PMC article.
Highly Cited. Review.
Ependymomas: development of immunotherapeutic strategies.
Ian F Pollack, Regina I Jakacki, Lisa H Butterfield, Hideho Okada.
Expert Rev Neurother, 2013 Oct 15; 13(10). PMID: 24117271    Free PMC article.
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.
Grégoire Wieërs, Nathalie Demotte, Danièle Godelaine, Pierre Van der Bruggen.
Cancers (Basel), 2011 Jan 01; 3(3). PMID: 24212939    Free PMC article.
Cytokines in cancer immunotherapy.
Sylvia Lee, Kim Margolin.
Cancers (Basel), 2011 Jan 01; 3(4). PMID: 24213115    Free PMC article.
Highly Cited.
Biology of human cutaneous melanoma.
Elias G Elias, Joanne H Hasskamp, Bhuvnesh K Sharma.
Cancers (Basel), 2010 Jan 01; 2(1). PMID: 24281039    Free PMC article.
Bioelectric applications for treatment of melanoma.
Stephen J Beebe, Karl H Schoenbach, Richard Heller.
Cancers (Basel), 2010 Jan 01; 2(3). PMID: 24281185    Free PMC article.
A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.
Nobuaki Suzuki, Shoichi Hazama, +7 authors, Masaaki Oka.
J Immunother, 2013 Dec 10; 37(1). PMID: 24316554    Free PMC article.
Progress in the development of a therapeutic vaccine for breast cancer.
Andrew L Coveler, Nicole E Bates, Mary L Disis.
Breast Cancer (Dove Med Press), 2010 Jan 01; 2. PMID: 24367164    Free PMC article.
Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity.
Aleksandra M Dudek, Shaun Martin, Abhishek D Garg, Patrizia Agostinis.
Front Immunol, 2014 Jan 01; 4. PMID: 24376443    Free PMC article.
Highly Cited. Review.
High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines.
Robert O Dillman, Carol Depriest, Stephanie E McClure.
Cancer Biother Radiopharm, 2014 Jan 02; 29(2). PMID: 24380630    Free PMC article.
Dendritic cell-based immunotherapy for myeloid leukemias.
Christian M Schürch, Carsten Riether, Adrian F Ochsenbein.
Front Immunol, 2014 Jan 16; 4. PMID: 24427158    Free PMC article.
Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.
Diana Llopiz, Eduardo Huarte, +7 authors, Pablo Sarobe.
Oncoimmunology, 2014 Feb 06; 2(12). PMID: 24498563    Free PMC article.
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
Osama E Rahma, J Michael Hamilton, +5 authors, Samir N Khleif.
J Transl Med, 2014 Feb 26; 12. PMID: 24565030    Free PMC article.
Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes.
Jonathan A Trujillo, Stephanie Gras, +5 authors, Stanley Perlman.
J Immunol, 2014 May 06; 192(11). PMID: 24795457    Free PMC article.
Therapeutic vaccines for cancer: an overview of clinical trials.
Ignacio Melero, Gustav Gaudernack, +8 authors, Håkan Mellstedt.
Nat Rev Clin Oncol, 2014 Jul 09; 11(9). PMID: 25001465
Highly Cited. Review.
Melanoma vaccines: mixed past, promising future.
Junko Ozao-Choy, Delphine J Lee, Mark B Faries.
Surg Clin North Am, 2014 Sep 24; 94(5). PMID: 25245965    Free PMC article.
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
Mira A Patel, Jennifer E Kim, +2 authors, Michael Lim.
Cancers (Basel), 2014 Oct 01; 6(4). PMID: 25268164    Free PMC article.
CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification.
Reiss A Reid, James E Redman, +3 authors, Stephen Man.
Immunology, 2014 Oct 07;. PMID: 25284607    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.
Florian Madura, Pierre J Rizkallah, +6 authors, Andrew K Sewell.
Eur J Immunol, 2014 Dec 05; 45(2). PMID: 25471691    Free PMC article.
Antigen-specific vaccines for cancer treatment.
Maria Tagliamonte, Annacarmen Petrizzo, +2 authors, Luigi Buonaguro.
Hum Vaccin Immunother, 2014 Dec 09; 10(11). PMID: 25483639    Free PMC article.
Novel dendritic cell-based vaccination in late stage melanoma.
Erika J Schneble, Xianzhong Yu, T E Wagner, George E Peoples.
Hum Vaccin Immunother, 2014 Dec 09; 10(11). PMID: 25483650    Free PMC article.
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).
Howard L Kaufman, Michael K Wong, +4 authors, Michael A Morse.
J Pers Med, 2015 Jan 07; 4(1). PMID: 25562142    Free PMC article.
Tumor cell lysates as immunogenic sources for cancer vaccine design.
Fermín E González, Alejandra Gleisner, +3 authors, Flavio Salazar-Onfray.
Hum Vaccin Immunother, 2015 Jan 28; 10(11). PMID: 25625929    Free PMC article.
Mouse model for pre-clinical study of human cancer immunotherapy.
Zhiya Ya, Yared Hailemichael, Willem Overwijk, Nicholas P Restifo.
Curr Protoc Immunol, 2015 Feb 03; 108. PMID: 25640991    Free PMC article.
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
Zili Wang, Esteban Celis.
Cancer Immunol Immunother, 2015 May 20; 64(8). PMID: 25986168    Free PMC article.
Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.
Yukiko Kiniwa, Jiang Li, +4 authors, Helen Y Wang.
PLoS One, 2015 May 21; 10(5). PMID: 25993655    Free PMC article.
Improving the safety of cell therapy with the TK-suicide gene.
Raffaella Greco, Giacomo Oliveira, +9 authors, Fabio Ciceri.
Front Pharmacol, 2015 May 23; 6. PMID: 25999859    Free PMC article.
Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma.
Jacek Mackiewicz, Aldona Karczewska-Dzionk, +6 authors, Andrzej Mackiewicz.
Medicine (Baltimore), 2015 May 29; 94(21). PMID: 26020391    Free PMC article.
CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis.
Qing Wang, David J Klinke, Zhijun Wang.
BMC Syst Biol, 2015 Jun 07; 9. PMID: 26048402    Free PMC article.
Harnessing the Microbiome to Enhance Cancer Immunotherapy.
Michelle H Nelson, Marshall A Diven, Logan W Huff, Chrystal M Paulos.
J Immunol Res, 2015 Jun 24; 2015. PMID: 26101781    Free PMC article.
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
David H Lawson, Sandra Lee, +8 authors, John M Kirkwood.
J Clin Oncol, 2015 Sep 10; 33(34). PMID: 26351350    Free PMC article.
Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.
Yuanxun Yang, Yan Jin, Wenxi Du.
Int J Clin Exp Pathol, 2015 Dec 01; 8(9). PMID: 26617804    Free PMC article.
T Cell Vaccinology: Beyond the Reflection of Infectious Responses.
Nathan D Pennock, Justin D Kedl, Ross M Kedl.
Trends Immunol, 2016 Feb 03; 37(3). PMID: 26830540    Free PMC article.
A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.
Valentina Bianchi, Anna Bulek, +6 authors, David K Cole.
J Biol Chem, 2016 Feb 27; 291(17). PMID: 26917722    Free PMC article.
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
Satoru Iwasa, Yasuhide Yamada, +13 authors, Kyogo Itoh.
Cancer Sci, 2016 Feb 28; 107(5). PMID: 26920496    Free PMC article.
Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.
Bracha Shraibman, Dganit Melamed Kadosh, Eilon Barnea, Arie Admon.
Mol Cell Proteomics, 2016 Jul 15; 15(9). PMID: 27412690    Free PMC article.
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Nobuaki Suzuki, Shoichi Hazama, +26 authors, Hiroaki Nagano.
Cancer Sci, 2016 Oct 27; 108(1). PMID: 27783849    Free PMC article.
Novel vaccines for glioblastoma: clinical update and perspective.
Evan K Winograd, Michael J Ciesielski, Robert A Fenstermaker.
Immunotherapy, 2016 Dec 21; 8(11). PMID: 27993092    Free PMC article.
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Rong-Fu Wang, Helen Y Wang.
Cell Res, 2016 Dec 28; 27(1). PMID: 28025978    Free PMC article.
Highly Cited. Review.
Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
Thaiz Rivera Vargas, Isis Benoit-Lizon, Lionel Apetoh.
Eur J Cancer, 2017 Feb 22; 75. PMID: 28219022    Free PMC article.
A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia.
Yukio Kobayashi, Toru Sakura, +3 authors, Yuji Heike.
Cancer Immunol Immunother, 2017 Mar 23; 66(7). PMID: 28321480    Free PMC article.
Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Hyun-Jung Sohn, Ji Yoon Lee, +4 authors, Tai-Gyu Kim.
Oncotarget, 2017 May 10; 8(27). PMID: 28477011    Free PMC article.
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Lisa H Butterfield, Fengmin Zhao, +8 authors, David H Lawson.
Clin Cancer Res, 2017 May 26; 23(17). PMID: 28536308    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy.
Xia Li, Mohamed A Shenashen, +3 authors, Sherif A Ei-Safty.
Sci Rep, 2017 Dec 03; 7(1). PMID: 29196724    Free PMC article.
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami-Chouaib.
Front Immunol, 2018 Feb 07; 9. PMID: 29403496    Free PMC article.
Highly Cited. Review.
Efficacy of intracellular immune checkpoint-silenced DC vaccine.
Danhong Wang, Xue F Huang, +20 authors, Hu Chen.
JCI Insight, 2018 Feb 09; 3(3). PMID: 29415891    Free PMC article.
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Jeremy M Grenier, Stephen T Yeung, Kamal M Khanna.
Front Immunol, 2018 Apr 07; 9. PMID: 29623082    Free PMC article.
Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
Brett J Hos, Elena Tondini, Sander I van Kasteren, Ferry Ossendorp.
Front Immunol, 2018 May 15; 9. PMID: 29755468    Free PMC article.
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Bracha Shraibman, Eilon Barnea, +34 authors, Arie Admon.
Mol Cell Proteomics, 2018 Aug 04; 17(11). PMID: 30072578    Free PMC article.
An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials.
Cody Chiuzan, Elizabeth Garrett-Mayer, Michael Nishimura.
Stat Biopharm Res, 2018 Dec 14; 10(3). PMID: 30524665    Free PMC article.
Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients.
Belinda Palermo, Ornella Franzese, +9 authors, Paola Nisticò.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524882    Free PMC article.
Peptide-based materials for cancer immunotherapy.
Lu Zhang, Yanyu Huang, +3 authors, Yuanpei Li.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695802    Free PMC article.
Immunotherapy for advanced melanoma.
Lei Fang, Anke S Lonsdorf, Sam T Hwang.
J Invest Dermatol, 2008 Oct 18; 128(11). PMID: 18927541    Free PMC article.
Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.
Nathalie Vigneron, Violette Ferrari, +2 authors, Ralf M Leonhardt.
J Immunol, 2018 Aug 24; 201(7). PMID: 30135181    Free PMC article.
Breaking tolerance with engineered class I antigen-presenting molecules.
Christopher A Parks, Kalli R Henning, +10 authors, Larry R Pease.
Proc Natl Acad Sci U S A, 2019 Feb 08; 116(8). PMID: 30728302    Free PMC article.
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Bracha Shraibman, Eilon Barnea, +34 authors, Arie Admon.
Mol Cell Proteomics, 2019 Jun 04; 18(6). PMID: 31154438    Free PMC article.
Overlapping synthetic peptides as vaccines.
Shisong Jiang, Ruijiang Song, +2 authors, Ruth M Ruprecht.
Vaccine, 2006 Jun 24; 24(37-39). PMID: 16793181    Free PMC article.
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
Shigetaka Suekane, Shigeru Yutani, +16 authors, Masanori Noguchi.
Int J Oncol, 2020 Apr 03; 56(6). PMID: 32236612    Free PMC article.
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Masanori Noguchi, Gaku Arai, +13 authors, Kyogo Itoh.
Cancer Immunol Immunother, 2020 Feb 07; 69(5). PMID: 32025848    Free PMC article.
Normalization Cancer Immunotherapy for Melanoma.
Matthew D Vesely, Lieping Chen.
J Invest Dermatol, 2020 Feb 25; 140(6). PMID: 32092349    Free PMC article.
Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.
Hakimeh Ebrahimi-Nik, Justine Michaux, +8 authors, Pramod K Srivastava.
JCI Insight, 2019 Jun 21; 5. PMID: 31219806    Free PMC article.
T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope.
Mesha Saeed, Erik Schooten, +3 authors, Reno Debets.
Cancers (Basel), 2020 May 21; 12(5). PMID: 32429338    Free PMC article.
Current Options and Future Directions in Immune Therapy for Glioblastoma.
John Lynes, Victoria Sanchez, +2 authors, Edjah Nduom.
Front Oncol, 2018 Dec 21; 8. PMID: 30568917    Free PMC article.
Selecting Target Antigens for Cancer Vaccine Development.
Luigi Buonaguro, Maria Tagliamonte.
Vaccines (Basel), 2020 Oct 22; 8(4). PMID: 33080888    Free PMC article.
Therapeutic vaccination targeting CD40 and TLR3 controls melanoma growth through existing intratumoral CD8 T cells without new T cell infiltration.
Aaron D Stevens, Timothy N J Bullock.
Cancer Immunol Immunother, 2021 Jan 17; 70(8). PMID: 33452626    Free PMC article.
An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection.
Cory A Brennick, Mariam M George, +10 authors, Pramod K Srivastava.
J Clin Invest, 2020 Dec 16; 131(3). PMID: 33320837    Free PMC article.
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.
Heather F Jones, Zaki Molvi, +2 authors, David A Scheinberg.
Front Immunol, 2021 Feb 12; 11. PMID: 33569049    Free PMC article.
Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy.
Beatrice Cavalluzzo, Concetta Ragone, +7 authors, Maria Tagliamonte.
J Transl Med, 2021 Feb 28; 19(1). PMID: 33637105    Free PMC article.
Tumor rejection properties of gp100209-specific T cells correlate with T cell receptor binding affinity towards the wild type rather than anchor-modified antigen.
Jesus A Alonso, Angela R Smith, Brian M Baker.
Mol Immunol, 2021 May 15; 135. PMID: 33990005    Free PMC article.
Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
Ira Surolia, James Gulley, Ravi A Madan.
Expert Opin Biol Ther, 2014 Sep 13; 14(12). PMID: 25212872    Free PMC article.
The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community.
Zeynep Koşaloğlu-Yalçın, Nina Blazeska, +8 authors, Alessandro Sette.
Front Immunol, 2021 Sep 11; 12. PMID: 34504503    Free PMC article.
A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma.
P Lau, M Shen, +5 authors, H Liu.
J Eur Acad Dermatol Venereol, 2021 Jun 03; 35(10). PMID: 34077578    Free PMC article.
H2-M and H2-O as Targeting Vehicles for the MHC Class II Processing Compartment Promote Antigen-Specific CD4+ T Cell Activation.
Lucia Lapazio, Monika Braun, Kaj Grandien.
Vaccines (Basel), 2021 Oct 27; 9(10). PMID: 34696161    Free PMC article.
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Alexandre Harari, Apostolos Sarivalasis, +9 authors, Lana E Kandalaft.
Cancers (Basel), 2021 Nov 28; 13(22). PMID: 34830955    Free PMC article.
The role of cancer stem cells in the modulation of anti-tumor immune responses.
Cristina Maccalli, Kakil Ibrahim Rasul, Mamoun Elawad, Soldano Ferrone.
Semin Cancer Biol, 2018 Sep 28; 53. PMID: 30261276    Free PMC article.
Methods for improving the immunogenicity and efficacy of cancer vaccines.
Lorenzo Pilla, Soldano Ferrone, Cristina Maccalli.
Expert Opin Biol Ther, 2018 Jun 08; 18(7). PMID: 29874943    Free PMC article.
Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments.
Kermit S Zhang, Tomer Pelleg, +3 authors, Susanti Ie.
Melanoma Manag, 2021 Dec 14; 8(3). PMID: 34900220    Free PMC article.
Antitumor Peptide-Based Vaccine in the Limelight.
Takumi Kumai, Hidekiyo Yamaki, +3 authors, Hiroki Komatsuda.
Vaccines (Basel), 2022 Jan 23; 10(1). PMID: 35062731    Free PMC article.
Identification of promising CD8 and CD4 T cell epitopes for peptide vaccine formulation against SARS-CoV-2.
Supriyo Chakraborty, Bornali Deb, Durbba Nath, Deboja Monoswita.
Arch Microbiol, 2022 Apr 06; 204(5). PMID: 35380253    Free PMC article.
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients.
Michael M Wach, John R Subjeck, +7 authors, John M Kane.
Melanoma Res, 2022 Mar 08; 32(2). PMID: 35254331    Free PMC article.